1-2 of 2
Sharmeen Mansoor
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Final Results and Follow-up of a Phase I Study of the Fc Engineered CD19 Antibody XmAb®5574 (aka MOR00208) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Jennifer A. Woyach, MD, Farrukh Awan, MD MS, Ian Flinn, Jesus G. Berdeja, MD, Elizabeth A Wiley, Sharmeen Mansoor, Ying Huang, MA, MS, Gerard Lozanski, MD, Paul A. Foster, MD, John C. Byrd, MD
Journal: Blood
Blood (2014) 124 (21): 1993.
https://doi.org/10.1182/blood.V124.21.1993.1993
Published: 2014
Journal Articles

A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL

Clinical Trials & Observations
Jennifer A. Woyach, Farrukh Awan, Ian W. Flinn, Jesus G. Berdeja, Elizabeth Wiley, Sharmeen Mansoor, Ying Huang, Gerard Lozanski, Paul A. Foster, John C. Byrd
Journal: Blood
Blood (2014) 124 (24): 3553–3560.
https://doi.org/10.1182/blood-2014-08-593269
Published: 2014
Includes: Supplemental data